UY39603A - Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso - Google Patents

Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso

Info

Publication number
UY39603A
UY39603A UY0001039603A UY39603A UY39603A UY 39603 A UY39603 A UY 39603A UY 0001039603 A UY0001039603 A UY 0001039603A UY 39603 A UY39603 A UY 39603A UY 39603 A UY39603 A UY 39603A
Authority
UY
Uruguay
Prior art keywords
methods
cystic fibrosis
modulators
regulatory protein
transmembrane conductance
Prior art date
Application number
UY0001039603A
Other languages
English (en)
Inventor
Andrew Bogdan
David Hardee
R Hodges Timothy
Henry Korman
Li Huan-Qiu
R Schrimpf Michael
Original Assignee
Abbvie Global Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Global Entpr Ltd filed Critical Abbvie Global Entpr Ltd
Publication of UY39603A publication Critical patent/UY39603A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención proporciona compuestos de formula (I) en donde R1 tiene cualquiera de los valores definidos en la memoria descriptiva, y sales farmacéuticamente aceptables de estos, composiciones farmaceuticas que los comprenden y métodos para tratar la fibrosis quística mediante la administración de un compuesto de la invención.
UY0001039603A 2021-01-06 2022-01-04 Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso UY39603A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163134392P 2021-01-06 2021-01-06

Publications (1)

Publication Number Publication Date
UY39603A true UY39603A (es) 2022-07-29

Family

ID=80349654

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039603A UY39603A (es) 2021-01-06 2022-01-04 Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso

Country Status (6)

Country Link
US (2) US20220213041A1 (es)
JP (1) JP2022106285A (es)
AR (1) AR124574A1 (es)
TW (1) TW202241851A (es)
UY (1) UY39603A (es)
WO (1) WO2022150173A1 (es)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2569402A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
ES2656017T3 (es) 2004-06-24 2018-02-22 Vertex Pharmaceuticals Incorporated Moduladores de transportadores del casete de unión a ATP
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
EP2170901B1 (en) 2007-05-25 2015-07-01 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP2231280B1 (en) 2007-12-10 2016-08-10 Novartis AG Amiloride-like Pyrazine-carboxamides as ENaC blockers
AU2008335031B2 (en) 2007-12-13 2013-11-28 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
MX2011004374A (es) 2008-10-23 2011-05-23 Vertex Pharma Formas solidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2-(trifluo rometil)fenil)-4-oxo-5-(trifluorometil)-1,4-dihidroquinolin-3-car boxamida.
US8367660B2 (en) 2008-12-30 2013-02-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
EP2624695B1 (en) 2010-10-08 2015-09-23 Nivalis Therapeutics, Inc. Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
EP2760463B1 (en) 2011-09-20 2018-11-21 The University of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
CA2911453C (en) 2013-05-07 2021-08-03 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis.
MY176814A (en) 2013-08-08 2020-08-21 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
AU2015229117A1 (en) 2014-03-13 2016-09-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
EP3116501A1 (en) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
ES2830279T3 (es) 2014-10-31 2021-06-03 Abbvie Overseas Sarl Cromanos sustituidos y método de uso
CA2966023A1 (en) 2014-10-31 2016-05-06 Abbvie S.A.R.L. Substituted tetrahydropyrans and method of use
AU2016272702A1 (en) 2015-06-02 2017-12-21 Abbvie S.A.R.L. Substituted pyridines and method of use
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
WO2017060873A1 (en) 2015-10-09 2017-04-13 AbbVie S.à.r.l. Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use
WO2017060874A1 (en) 2015-10-09 2017-04-13 Abbvie S.Á.R.L N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
CN109219602A (zh) 2016-04-26 2019-01-15 艾伯维公司 囊性纤维化跨膜传导调节物蛋白的调节剂
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US20180133046A1 (en) 2016-11-17 2018-05-17 Osteodirit, Inc. Custom spinal orthosis, methodology and wear compliance
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US10988454B2 (en) * 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
GB201801355D0 (en) 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
AR124574A1 (es) 2023-04-12
JP2022106285A (ja) 2022-07-19
US20220213041A1 (en) 2022-07-07
US20240043386A1 (en) 2024-02-08
WO2022150173A1 (en) 2022-07-14
TW202241851A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
ECSP19048759A (es) Modulador del regulador de conductancia de transmembrana de fibrosis quística, composiciones farmacéuticas, y proceso para producir el modulador
UY37617A (es) Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo
CO2022002634A2 (es) Formas cristalinas de moduladores del cftr
ECSP22052564A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
CO2021014204A2 (es) Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
DOP2019000081A (es) Modulador del regulador de conductancia de transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
CL2020002698A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CL2013003313A1 (es) Compuestos derivados de 2,4-diaminoquinazolinas, sales o solvatos farmacéuticamente aceptables; composición farmacéutica que los comprende; y uso en el tratamiento de un trastorno en el que interviene la modulación de tlr7 y/o tlr8.
CO2019002618A2 (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
CO2022004698A2 (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CL2023000655A1 (es) Degradadores de helios basados en pequeñas moléculas de piperidinilo; y uso
BR112022022669A2 (pt) Inibidores de nek7 quinase
CO2019002616A2 (es) Compuestos de indazol para usar en lesiones de tendones y/o ligamentos
ECSP23088732A (es) Moduladores de trex1
UY39603A (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso
UY39604A (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso
CO2018007610A2 (es) Derivados de indano y su uso en terapias
AR129032A1 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
AR126702A1 (es) Compuestos fosfolípidos y métodos de preparación y uso de los mismos
CL2023000926A1 (es) Inhibidores alostéricos de akt para su uso en el tratamiento de telangiectasia hemorrágica hereditaria
AR124430A1 (es) Inhibidores de arginasa y métodos de uso de ellos
CR20190211A (es) Modulador del regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador
CU23604B7 (es) Compuestos terapéuticos